国家药监局:孕妇禁用、过敏体质者慎用颈康制剂处方和非处方药

2020-04-10 董童 人民网-人民健康网

国家药监局于今日在官网发布《关于修订颈康制剂说明书的公告》(以下简称“公告”)称,根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对颈康制剂(包括片剂

国家药监局于今日在官网发布《关于修订颈康制剂说明书的公告》(以下简称“公告”)称,根据药品不良反应评估结果,为进一步保障公众用药安全,国家药品监督管理局决定对颈康制剂(包括片剂、胶囊剂)说明书【不良反应】、【禁忌】和【注意事项】项进行统一修订。修订要求显示,孕妇和对该药品及所含成份过敏者禁用,过敏体质者慎用颈康制剂处方和非处方药。

公告显示,所有颈康制剂生产企业均应依据原《药品注册管理办法》等有关规定,按照相应说明书修订要求,于2020年6月30日前报省级药品监管部门备案。各省级药品监管部门应当督促行政区域内上述药品的生产企业按要求做好相应说明书修订和标签、说明书更换工作,对违法违规行为依法严厉查处。

公告要求,修订内容涉及药品标签的,应当一并进行修订;说明书及标签其他内容应当与原批准内容一致。在备案之日起生产的药品,不得继续使用原药品说明书。生产企业应当在备案后6个月内对已出厂的药品说明书及标签予以更换。药品生产企业应当对新增不良反应发生机制开展深入研究,采取有效措施做好药品使用和安全性问题的宣传培训,指导医师和患者合理用药。

公告提醒,临床医师应当仔细阅读上述药品说明书的修订内容,在选择用药时,应当根据新修订说明书进行充分的获益/风险分析。患者用药前应当仔细阅读药品说明书,使用处方药的,应严格遵医嘱用药。

附:颈康制剂处方药说明书修订要求

一、【不良反应】项应当包括:

1.消化系统:恶心、呕吐、腹痛、腹泻、胃不适等,有肝生化指标异常个例报告。

2.皮肤及其附件:皮疹、瘙痒等。

3.其他:心悸、过敏反应等。

二、【禁忌】项应当包括:

1.孕妇禁用。

2.对本品及所含成份过敏者禁用。

三、【注意事项】项应当包括:

1.肝生化指标异常者慎用。

2.对本品及所含成份过敏者禁用,过敏体质者慎用。

颈康制剂非处方药说明书修订要求

一、【不良反应】项应当包括:

监测数据显示,颈康制剂有恶心、呕吐、腹痛、腹泻、胃不适、皮疹、瘙痒、心悸、过敏反应等不良反应报告,也有肝功能异常个例报告。

二、【禁忌】项应当包括:

1.孕妇禁用。

2.对本品及所含成份过敏者禁用。

三、【注意事项】项应当包括:

1.忌食生冷、油腻食物。

2.高血压、心脏病、糖尿病、肝病、肾病等患者应在医师指导下服用。

3.服药7天症状无缓解,应去医院就诊。

4.当使用本品出现不良反应时,应停药并及时就医。

5.对本品及所含成份过敏者禁用,过敏体质者慎用。

6.儿童、哺乳期妇女、年老体弱者应在医师指导下服用。

7.本品性状发生改变时禁止使用。

8.请将本品放在儿童不能接触的地方。

9.如正在使用其他药品,使用本品前请咨询医师或药师。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819212, encodeId=06071819212af, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Dec 21 09:37:35 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803482, encodeId=130880348241, content=好评, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 14:37:43 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301710, encodeId=e5a21301e103e, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429250, encodeId=6287142925092, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589658, encodeId=e098158965897, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819212, encodeId=06071819212af, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Dec 21 09:37:35 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803482, encodeId=130880348241, content=好评, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 14:37:43 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301710, encodeId=e5a21301e103e, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429250, encodeId=6287142925092, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589658, encodeId=e098158965897, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
    2020-07-20 ms7000001773953003

    好评

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1819212, encodeId=06071819212af, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Dec 21 09:37:35 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803482, encodeId=130880348241, content=好评, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 14:37:43 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301710, encodeId=e5a21301e103e, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429250, encodeId=6287142925092, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589658, encodeId=e098158965897, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
    2020-04-12 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819212, encodeId=06071819212af, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Dec 21 09:37:35 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803482, encodeId=130880348241, content=好评, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 14:37:43 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301710, encodeId=e5a21301e103e, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429250, encodeId=6287142925092, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589658, encodeId=e098158965897, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819212, encodeId=06071819212af, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Mon Dec 21 09:37:35 CST 2020, time=2020-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803482, encodeId=130880348241, content=好评, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acee5401612, createdName=ms7000001773953003, createdTime=Mon Jul 20 14:37:43 CST 2020, time=2020-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301710, encodeId=e5a21301e103e, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429250, encodeId=6287142925092, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589658, encodeId=e098158965897, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Sun Apr 12 05:37:35 CST 2020, time=2020-04-12, status=1, ipAttribution=)]

相关资讯

JACC:近一半的心脏病孕妇并发症是可预防的

妊娠可能导致心脏病妇女的并发症,这些并发症可能危及生命。了解严重的并发症以及如何预防是很重要的。本研究的主要目的是评估心脏病孕妇的严重心脏病事件(SCEs)的发生率,以及其是否可预防和对新生儿预后的影

很多人在疫情中怀孕了,还有 4,800 万不孕夫妇求医路漫

期待三代试管技术在我国能够从改善辅助生殖质量、更加合法依规、减少医疗纠纷等诸多方面迎来新的发展契机。

JCEM:孕妇B12、叶酸和同型半胱氨酸的浓度以及子代对应激的皮质醇和心血管反应

该研究的结果表明,孕妇单碳营养素的状况可能对子代的神经内分泌应激反应具有长期的影响。

Heart:中重度瓣膜疾病孕妇的预后研究

本荟萃分析的目的旨在评估来自中高等发展国家的中重度先天性心脏瓣膜病(VHD)孕妇的孕期/胎儿预后结局。

Lancet Infect Dis:新冠肺炎孕妇临床特点、产科和新生儿结局

研究发现,通过强化、积极的临床管理。晚期妊娠新冠肺炎产妇、胎儿和新生儿结局良好,妊娠期COVID-19患者的临床特征与非妊娠期COVID-19患者相似

Clin Infect Dis:接受治疗后,耐多药/耐利福平结核病孕妇的母婴结局

由于孕妇及其婴儿常被排除在临床试验和扩大准入方案之外,关于其二线结核病药物的安全性和疗效的数据非常有限。

拓展阅读

李利任国家药监局局长

9月6日,国务院任免国家工作人员。任命李扬为交通运输部副部长;任命王宏志为国务院国有资产监督管理委员会副主任;任命丁赤飚为中国科学院副院长;任命张姿(女)为国家国防科技工业局副局长;任命李利为国家药品

两部门:进出口麻醉和精神药品应取得国家药监局颁发的准许证

进口麻醉药品和精神药品无需办理进口药品通关单。

冰洲石生物自主研发的创新雌激素受体嵌合降解剂AC0682临床申请获国家药监局批准

专注于人工智能药物研发的临床阶段生物技术公司Accutar Biotechnology, Inc.今天宣布,国家药品监督管理局(NMPA)已批准该公司在研药物AC0682用于治疗雌激素受体阳性乳腺癌患

国家药监局全新批准12款药品,3个首仿、2个首家通过一致性评价

1月29日,药监局发布《2021年01月29日药品批准证明文件待领取信息》,内容显示12个药品获批,包括替格瑞洛、地氯雷他定、他达拉非、利伐沙班......

国家药监局通知,影响所有药企

重要药品文件将修订,影响所有药企